Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro
A limited number of effective therapies are currently available to treat human coronavirus SARS-CoV-2 and other human coronaviruses, which are responsible for nearly a third of global cases of the common cold. The possibility of new emerging coronaviruses demands powerful new antiviral strategies. L...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/4/972 |
| _version_ | 1827743355227865088 |
|---|---|
| author | Sabina Andreu Inés Ripa Raquel Bello-Morales José Antonio López-Guerrero |
| author_facet | Sabina Andreu Inés Ripa Raquel Bello-Morales José Antonio López-Guerrero |
| author_sort | Sabina Andreu |
| collection | DOAJ |
| description | A limited number of effective therapies are currently available to treat human coronavirus SARS-CoV-2 and other human coronaviruses, which are responsible for nearly a third of global cases of the common cold. The possibility of new emerging coronaviruses demands powerful new antiviral strategies. Lactoferrin is a well-known protein that possesses anti-inflammatory and immunomodulatory activities, and it has previously shown antiviral activity against several viruses, including SARS-CoV-2. To increase this antiviral activity, here we present bovine liposomal lactoferrin. Liposomal encapsulation of the compound was proven to increase permeability, bioavailability, and time release. In the present work, we compare the antiviral activity of free and liposomal bovine lactoferrin against HCoV229E and SARS-CoV-2 in vitro and in human primary bronchial epithelial cells, and we demonstrated that the liposomal form exerts a more potent antiviral activity than its free form at non-cytotoxic doses. |
| first_indexed | 2024-03-11T04:25:56Z |
| format | Article |
| id | doaj.art-2db7632be7474f82a547556c96f51a92 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-11T04:25:56Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-2db7632be7474f82a547556c96f51a922023-11-17T21:46:23ZengMDPI AGViruses1999-49152023-04-0115497210.3390/v15040972Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In VitroSabina Andreu0Inés Ripa1Raquel Bello-Morales2José Antonio López-Guerrero3Department of Molecular Biology, Universidad Autónoma de Madrid, C/Darwin, 2 Cantoblanco, 28049 Madrid, SpainDepartment of Molecular Biology, Universidad Autónoma de Madrid, C/Darwin, 2 Cantoblanco, 28049 Madrid, SpainDepartment of Molecular Biology, Universidad Autónoma de Madrid, C/Darwin, 2 Cantoblanco, 28049 Madrid, SpainDepartment of Molecular Biology, Universidad Autónoma de Madrid, C/Darwin, 2 Cantoblanco, 28049 Madrid, SpainA limited number of effective therapies are currently available to treat human coronavirus SARS-CoV-2 and other human coronaviruses, which are responsible for nearly a third of global cases of the common cold. The possibility of new emerging coronaviruses demands powerful new antiviral strategies. Lactoferrin is a well-known protein that possesses anti-inflammatory and immunomodulatory activities, and it has previously shown antiviral activity against several viruses, including SARS-CoV-2. To increase this antiviral activity, here we present bovine liposomal lactoferrin. Liposomal encapsulation of the compound was proven to increase permeability, bioavailability, and time release. In the present work, we compare the antiviral activity of free and liposomal bovine lactoferrin against HCoV229E and SARS-CoV-2 in vitro and in human primary bronchial epithelial cells, and we demonstrated that the liposomal form exerts a more potent antiviral activity than its free form at non-cytotoxic doses.https://www.mdpi.com/1999-4915/15/4/972lactoferrinliposomal lactoferrinantiviralsSARS-CoV-2COVID-19 |
| spellingShingle | Sabina Andreu Inés Ripa Raquel Bello-Morales José Antonio López-Guerrero Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro Viruses lactoferrin liposomal lactoferrin antivirals SARS-CoV-2 COVID-19 |
| title | Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro |
| title_full | Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro |
| title_fullStr | Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro |
| title_full_unstemmed | Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro |
| title_short | Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro |
| title_sort | liposomal lactoferrin exerts antiviral activity against hcov 229e and sars cov 2 pseudoviruses in vitro |
| topic | lactoferrin liposomal lactoferrin antivirals SARS-CoV-2 COVID-19 |
| url | https://www.mdpi.com/1999-4915/15/4/972 |
| work_keys_str_mv | AT sabinaandreu liposomallactoferrinexertsantiviralactivityagainsthcov229eandsarscov2pseudovirusesinvitro AT inesripa liposomallactoferrinexertsantiviralactivityagainsthcov229eandsarscov2pseudovirusesinvitro AT raquelbellomorales liposomallactoferrinexertsantiviralactivityagainsthcov229eandsarscov2pseudovirusesinvitro AT joseantoniolopezguerrero liposomallactoferrinexertsantiviralactivityagainsthcov229eandsarscov2pseudovirusesinvitro |